Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
Nasdaq3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Nasdaq12d
Eli Lilly's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
The Motley Fool5d
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Shares of pharmaceutical giant Eli Lilly have been falling in recent months. The company updated its guidance last week, and investors weren't impressed. It could be a tough year for Eli Lilly ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...